(A) Presence of PD-1, its ligands PD-L1 and PD-L2, and the phosphatases SHP-1, SHP-2, and SHP-2-like (SHP-2L) in representative jawed vertebrates, including sharks, ray-finned fish, amphibians, and ...

As Summit Therapeutics’ Chinese partner prepares to reveal data for a key trial at ASCO, analysts consider the impact on rivals Merck, Bristol Myers Squibb and BioNTech.

Drugmakers including BioNTech, Merck & Co. and Pfizer are all testing their investigational PD-1/VEGF bispecifics against ...

Despite recent advances in immunotherapy and targeted therapy, most patients with non-small-cell lung cancer (NSCLC) continue to have disease progression and develop resistance to current treatments.

A simplified schematic illustrating how cancer cells evade immune attack by expressing PD-L1, which binds to PD-1 on T cells and suppresses their activity. The figure also shows how immune checkpoint ...

Molecular predictors and mechanisms of immune checkpoint inhibitor-induced myocarditis: A case-control study with translational correlates. Predictive factors for cardiac events following concurrent ...